Education
About Us
Working with TipRanks
Follow Us
Avidity Biosciences Inc (RNA)
NASDAQ:RNA
RNA Stock Chart & Stats
$70.80
-$0.39(-1.27%)
At close: 4:00 PM EST
$70.80
-$0.39(-1.27%)
Day’s Range― - ―
52-Week Range$21.51 - $71.09
Previous CloseN/A
Volume185.29K
Average Volume (3M)7.36M
Market Cap
$10.67B
Enterprise Value$4.18B
Total Cash (Recent Filing)$1.88B
Total Debt (Recent Filing)$49.97M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Mar 03, 2026EPS Estimate
-1.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding150,675,740
10 Day Avg. Volume5,154,564
30 Day Avg. Volume7,361,539
Financial Highlights & Ratios
PEG Ratio14.65
Price to Book (P/B)2.28
Price to Sales (P/S)297.77
P/FCF Ratio-10.54
Enterprise Value/Market Cap0.39
Enterprise Value/Revenue200.41
Enterprise Value/Gross Profit-35.67
Enterprise Value/Ebitda-7.03
Forecast
1Y Price Target
$71.71Price Target Upside1.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)-4.32
Revenue Forecast (FY)$15.32M
Bulls Say, Bears Say
Bulls Say
Acquisition PremiumThe acquisition by Novartis includes a 46% premium over Avidity's prior closing price, highlighting a substantial valuation uplift for shareholders.
Innovative PlatformThe acquisition highlights the innovative potential of Avidity's AOC platform, with upcoming BLAs supported by encouraging data and a high probability of approval.
Strategic ExpansionNovartis' acquisition of RNA is strategically aligned with its intent to expand its neuroscience and rare disease portfolio, supported by Avidity’s late-stage AOC pipeline.
Bears Say
Downgrade And Price TargetThe analyst has downgraded the stock to Hold and decreased the price target to $74, reflecting the deal terms and platform value for SpinCo.
Investment RisksRisks to the investment thesis include potential failures in clinical studies and challenges in securing regulatory approval for key assets.
Net LossRNA reported a net loss of $174.4M, reflecting ongoing financial challenges.
Avidity Biosciences News
RNA FAQ
What was Avidity Biosciences Inc’s price range in the past 12 months?
Avidity Biosciences Inc lowest stock price was $21.51 and its highest was $71.09 in the past 12 months.
What is Avidity Biosciences Inc’s market cap?
Avidity Biosciences Inc’s market cap is $10.67B.
When is Avidity Biosciences Inc’s upcoming earnings report date?
Avidity Biosciences Inc’s upcoming earnings report date is Mar 03, 2026 which is in 105 days.
How were Avidity Biosciences Inc’s earnings last quarter?
Avidity Biosciences Inc released its earnings results on Nov 10, 2025. The company reported -$1.27 earnings per share for the quarter, missing the consensus estimate of -$1.085 by -$0.185.
Is Avidity Biosciences Inc overvalued?
According to Wall Street analysts Avidity Biosciences Inc’s price is currently Undervalued.
Does Avidity Biosciences Inc pay dividends?
Avidity Biosciences Inc does not currently pay dividends.
What is Avidity Biosciences Inc’s EPS estimate?
Avidity Biosciences Inc’s EPS estimate is -1.19.
How many shares outstanding does Avidity Biosciences Inc have?
Avidity Biosciences Inc has 150,675,740 shares outstanding.
What happened to Avidity Biosciences Inc’s price movement after its last earnings report?
Avidity Biosciences Inc reported an EPS of -$1.27 in its last earnings report, missing expectations of -$1.085. Following the earnings report the stock price went up 1.231%.
Which hedge fund is a major shareholder of Avidity Biosciences Inc?
Currently, no hedge funds are holding shares in RNA
Avidity Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$71.71 (1.29% Upside)
$71.71 (1.29% Upside)
Blogger Sentiment
Bullish
RNA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 536.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 7.6%
Last 30 Days ▼ 7.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.68%
12-Months-Change
Fundamentals
Return on Equity
-32.44%
Trailing 12-Months
Asset Growth
30.07%
Trailing 12-Months
Company Description
Avidity Biosciences Inc
Avidity Biosciences is a biotechnology company focused on developing innovative RNA-targeted therapies for the treatment of various diseases, including serious genetic disorders and cancers. The company specializes in its proprietary Avidity Technology, which enables the delivery of RNA therapeutics directly to specific tissues and cells, enhancing the efficacy and safety of treatments. Avidity is primarily engaged in the development of its product pipeline, which includes preclinical and clinical-stage candidates designed to address unmet medical needs in multiple therapeutic areas.
RNA Stock 12 Month Forecast
Average Price Target
$71.71
▲(1.29% Upside)
Technical Analysis
PTC Therapeutics
―
Merus
―
Crispr Therapeutics AG
―
Rhythm Pharmaceuticals
―
Immunovant
―
Ownership Overview
0.71% Insiders
29.22% Mutual Funds
4.51% Other Institutional Investors
51.56% Public Companies and
Individual Investors